Palexia

Active Ingredient:: Tapentadol Hydrochloride
Origin:: EU

Palexia (Tapentadol Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Tapentadol hydrochloride, the active ingredient in Palexia, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe pain in adult patients when other analgesics are inadequate. GNH India supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Grünenthal B.V.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Tapentadol hydrochloride is used in the management of pain through central nervous system pathways.

Acute postoperative pain: provides analgesia after surgical procedures.
Chronic musculoskeletal pain: helps control persistent pain from conditions such as osteoarthritis.
Neuropathic pain associated with diabetic peripheral neuropathy: reduces pain intensity in affected patients.
Cancer‑related pain: contributes to overall pain control in oncology settings.
Severe breakthrough pain: offers rapid relief when baseline analgesia is insufficient.

How It Works

Tapentadol hydrochloride acts as a μ‑opioid receptor agonist and a norepinephrine reuptake inhibitor. By binding to μ‑opioid receptors it reduces neuronal excitability, while inhibition of norepinephrine reuptake enhances descending inhibitory pain pathways, together producing analgesia without the full opioid‑related side‑effect profile of traditional opioids.

Side Effects

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

Nausea and vomiting
Constipation
Dizziness or light‑headedness
Headache
Somnolence or fatigue
Dry mouth

Serious or Rare Side Effects

Respiratory depression
Seizures
Severe hypotension
Serotonin syndrome (when combined with serotonergic agents)
Allergic reactions such as angio‑edema or anaphylaxis
Dependence, abuse potential or withdrawal symptoms

Precautions & Warnings

When prescribing Tapentadol, clinicians should consider several safety aspects.

Assess pain severity and prior opioid exposure: ensure appropriate indication before initiating therapy.
Monitor for respiratory depression: especially during dose escalation or in patients with pulmonary disease.
Evaluate renal and hepatic function: dose adjustments may be required in impairment.
Avoid use with other central nervous system depressants: increased risk of sedation and respiratory effects.
Counsel patients on signs of dependence and proper disposal.
Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Tapentadol interacts with several drug classes that can modify its safety or efficacy.

Major Interactions (Avoid)

MAO inhibitors: risk of hypertensive crisis and serotonin syndrome.
CNS depressants (benzodiazepines, barbiturates, alcohol): additive respiratory depression.
Serotonergic agents (SSRIs, SNRIs, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

CYP2D6 inhibitors (quinidine, fluoxetine): may increase tapentadol plasma levels.
CYP3A4 inducers (rifampicin, carbamazepine): may reduce analgesic effect.
Diuretics: potential for enhanced hypotensive response.
Antihistamines: may increase sedation.
Anticonvulsants: monitor seizure threshold.

Frequently Asked Questions

Palexia contains tapentadol hydrochloride and is prescribed for the management of moderate to severe pain, including postoperative pain, chronic musculoskeletal pain, cancer‑related pain, and neuropathic pain when other analgesics are insufficient.

Tapentadol combines μ‑opioid receptor agonism with inhibition of norepinephrine reuptake. This dual action reduces pain signal transmission in the central nervous system and strengthens descending inhibitory pathways, providing effective analgesia.

The dose of Palexia is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and overall health status. The prescriber determines the appropriate strength, frequency and duration of therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.